share_log

Short Interest in BetterLife Pharma Inc. (OTCMKTS:BETRF) Decreases By 38.1%

Financial News Live ·  Oct 29, 2022 03:51

BetterLife Pharma Inc. (OTCMKTS:BETRF – Get Rating) was the recipient of a significant drop in short interest in October. As of October 15th, there was short interest totalling 35,700 shares, a drop of 38.1% from the September 30th total of 57,700 shares. Based on an average trading volume of 30,300 shares, the days-to-cover ratio is presently 1.2 days.

BetterLife Pharma Price Performance

Shares of OTCMKTS BETRF remained flat at $0.13 during mid-day trading on Friday. 82,052 shares of the company traded hands, compared to its average volume of 25,495. BetterLife Pharma has a 12 month low of $0.05 and a 12 month high of $0.30. The business's 50-day moving average price is $0.14 and its 200 day moving average price is $0.11.

Get BetterLife Pharma alerts:

About BetterLife Pharma

(Get Rating)

BetterLife Pharma Inc, a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections.

Featured Stories

  • Get a free copy of the StockNews.com research report on BetterLife Pharma (BETRF)
  • McDonald's Stock Sizzles, but Will it Hit a New All-Time High?
  • Chevron Gushes More Profits; Is it Time for Investors to Buy?
  • Will Ryanair Stock Gains, Strong Estimates Help it Fly?
  • Apple Inc. Stock Q4 Results Beat Negative Outlook, Stock Rises
  • Why is Amazon Stock Falling? Is the Sell-Off Overdone?

Receive News & Ratings for BetterLife Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BetterLife Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment